Article Sidebar

Submitted
10 January 2021
Accepted
11 January 2021
Published
31 December 2019
Download
PDF
Statistic
Read Counter : 559 Download : 649

Main Article Content

Abstract

The wound healing process is major cause of glaucoma surgery failure and enhances the incapability of controlling the IOP. This aim of study was to evaluate the angiogenesis effect of Bevacizumab injection on the amount and density of blood vessels in the rabbit model after trabeculectomy. It was a true experimental study using 16 eyes of 16 New Zealand White Rabbit (Oryctolagus cuniculus) that divided into two groups. The control group was treated with 0.05 ml of Balanced Saline Solution (BSS). The experimental group was treated with subconjunctival injection of 1.25 mg Bevacizumab in 0.05 BSS. All rabbit was sacrificed, and the eye was enucleated. Thus, the bleb area was dissected after 14 days. Histopathological analysis was performed to evaluate the amount and density of blood vessels. The mean amount of blood vessels in the control group was 22.63 ± 11.02, and the experimental group was 14,75 ± 4.92 (p=0.043). The mean of blood vessel density in the control group was 19.10 ± 1.69 %, and the experimental group was 16.53 ± 2.90 % (p=0.029)%. There was a statistically significant difference between the two groups (p<0.05). Subconjunctival bevacizumab in the rabbit model reduces the amount and density of blood vessels compared with subconjunctival BSS injection.

Keywords

Angiogenesis bevacizumab amount of blood vessel density of blood vessel trabeculectomy

Article Details

License

Copyright (c) 2019 Folia Medica Indonesiana

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

How to Cite
Nurwasis, N., Yuliawati, D., Komaratih, E., & Heriyawati, H. (2019). The Effect of Subconjunctival Bevacizumab on Angiogenesis in Rabbit Model. Folia Medica Indonesiana, 55(4), 290–294. https://doi.org/10.20473/fmi.v55i4.24465
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Cioffi GA, Durcan FJ, Girkin CA, Gupta, N Piltz-Seymour JR, Samuelson TW (2015). Basic and clinical science course: Glaucoma. San Fransisco, American Academy of Ophthalmology
  2. How A, Chua JL, Charlton A, Su R, Lim M, Kumar RS, Crowston JG, Wong TT (2010). Combined treatment with bevacizumab and s-fluorouracil attenuates the postoperative scarring response after experimental glaucoma filtration surgery. Invest Ophthalmol Vis Sci 51, 928-932
  3. Lama PJ, Fechner RD (2003). Antifibrotics and Wound Healing in Glaucoma Surgery. Surv Ophthalmol 48, 314-346
  4. Li Z, Bergen TV, Veire SV, Vel IV, Moreau H, Dewerchin M, Maudgal PC, Zeyen T, Spileers, W, Moons L, Stalmans I (2009). Inhibition of Vascular Endothelial Growth Factor Reduces Scar Formation after Glaucoma Filtration Surgery. Investigative Ophthalmology & Visual Science 50, 5217-5225
  5. Memarzadeh F, Varma R, Lin LT, Parikh JG, Dustin L, Alcaraz A, Eliott D (2009). Postoperative Use of Bevacizumab as an Antifibrotic Agent in Glaucoma Filtration Surgery in the Rabbit. Invest Ophthalmol Vis Sci 50, 3233-37
  6. Mietz H (2004). Wound Modulation in Glaucoma Surgery dalam Ghren, F. & Stamper, R. (Eds.). Essential in Ophthalmology: Glaucoma. Berlin, Springer-Verlag
  7. Ozgonul C, Mumcuoglu T, Gunal A (2014). The effect of bevacizumab on wound healing modulation in an experimental trabeculectomy model. Current Eye Research 39, 451-459
  8. Quigley H, Broman AT (2006). The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmology 90, 262-267
  9. Sheha, H. (2011). Update on modulating wound healing in trabeculectomy. In S Rumelt (Ed.). Glaucoma-Basic and Clinical Concept. Intech. Available at http:// www.intechopen.com/books/glaucoma-basic-and-clinical-concepts/update-on modulating-wound-healing- in-trabeculectomy. Accessed July 9, 2019.
  10. Skuta GL, Parrish RK (1987). Wound healing in glaucoma filtration surgery. Surv of Ophthalmology 32, 149-70
  11. Stamper RL, Lieberman MF, Drake MV (2009). Introduction and classification of the glaucomas dalam RL Stamper, MF Lieberman, MV Drake (Eds.). Becker-Schaeffer's Diagnosis and Therapy of the Glaucomas (8th Ed.). UK, Mosby Elsevier
  12. Valerie Gerriets, Anup Kasi (2019). Bevacizumab. USA, StatPearls Publishing LLC.
  13. Xiaoyan Liu, MM Liang Du PhD, Ni Li MD (2016). The effects of bevacizumab in augmenting trabeculectomy for glaucoma: A systematic review and meta-analysis of randomized controlled trials. Medicine 95, 15